High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy

Clinical Pharmacokinetics

Volumn 44, Issue 12, 2005, Pages 1267-1278

  Goujard, Cécile ^a   Legrand, Mayeule ^b,c   Panhard, Xavière ^c   Diquet, Bertrand ^b   Duval, Xavier ^c   Peytavin, Gilles ^c   Vincent, Isabelle ^a   Katlama, Christine ^b   Leport, Catherine ^c   Bonnet, Bénédicte ^d   Salmon Céron, Dominique ^e   Mentré, France ^c   Taburet, Anne Marie ^a  

^a BICÊTRE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MULTICENTER STUDIES; NELFINAVIR; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RITONAVIR; VIRAL LOAD;

EID: 29244450454     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544120-00005     Document Type: Article

References (59)

1. Jordan R, Gold L, Cummins C, et al. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. Br J Med 2002; 324: 1-10
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
3. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304
4. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 Suppl. 1: S142-8
5. Fletcher C, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000; 14: 2495-501
6. Flexner CW. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitors therapy and outcomes of patients with HIV infection. Ann Intern Med 2000; 133: 21-30
8. Piscitelli S, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344: 984-96
9. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16: 1131-8
10. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-9
11. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16: 551-60
12. Masquelier B, Peytavin G, Leport C, et al. Mechanisms of early virologic failure in antiretroviral naive patients starting protease inhibitor containing regimens: the Aprovir Study. J Infect Dis 2002; 186: 1503-7
13. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resis-tance mutations (Viraphar study). AIDS 2002; 16: 1331-40
14. Le Moing V, Peytavin G, Journot V, et al. Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 34: 497-9
15. Dieleman JP, Gyssens IC, Van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8
16. Reijers MH, Weigel HM, Hart AA, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000; 14: 59-68
17. Treluyer JM, Morini JP, Dimet J, et al. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus infected patients. Antimicrob Agents Chemother 2002; 46: 4009-12
18. Clayette P, Jorajuria S, Dormont D. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 235-6
19. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-42
20. Lin JH, Yamazaki M. Role of p-glycoprotein in pharmacokinetics. Clin Pharmacokinet 2003; 42: 59-98
21. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P4503A substrates. Clin Pharmacokinet 2003; 42: 969-4
22. Aarnoutse RE, Schapiro JM, Boucher CA, et al. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63: 741-53
23. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl. 1: S5-S37
24. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment naive HIV-1 infected individuals. AIDS 2003; 17: 1157-65
25. Flexner CW, Piscitelli SC. Concentration targeted therapy and the future of HIV management. AIDS 2002; 16 Suppl. 1: S1-3
26. Flexner CW, Piscitelli SC. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16: S1-S39
27. Kakuda TN, Page LM, Anderson PL, et al. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother 2001; 45: 236-42
28. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO Cohort. J Acquir Immune Defic Syndr 2001; 28: 232-9
29. Aymard G, Legrand M, Trichereau N, et al. Determination of twelve antiretroviral agents in human plasma sample using reverse-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 2000; 744: 227-40
30. Bouley M, Briere C, Padoin C, et al. Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir and saquinavir in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 2001; 23: 56-60
31. Dailly E, Thomas L, Kergueris MF, et al. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, nelfinavir, ritonavir, saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B Biomed Appl 2001; 758: 129-35
32. Lamotte C, Peytavin G, Farinotti R. Determination of nelfinavir, a potent protease inhibitor and its metabolite M8 in human plasma sample by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Appl 1999; 735: 159-70
33. Poirier JM, Robidou P, Jaillon P. Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Ther Drug Monit 1999; 21: 404-10
34. Proust V, Toth K, Hulin A, et al. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B Biomed Appl 2000; 742: 453-8
35. Legrand M, Taburet AM, Diquet B. COPHAR quality controls for PI quantification [abstract 8.3]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 April 2-4; Noordwijk, The Netherlands
36. Pinheiro JC, Bates DM. Mixed-effects models in S and Splus. New York: Springer-Verlag, 2000
37. Ghosn J, Lamotte C, Ait-Mohand H, et al. Efficacy of a twice-daily antiretroviral regimen containing 100mg ritonavir/400mg indinavir in HIV infected patients. AIDS 2003; 17:209-14
38. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47: 130-7
39. Saah AJ, Winchell GA, Nessly ML, et al. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2710-5
40. DiCenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47: 1929-35
41. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 2004; 48: 3226-32
42. Burger D, Hugen PWH, Aarnoutse RE, et al. A retrospective, cohort based survey of patients using twice daily indinavir+ritonavir combinations: pharmacokinetics, safety and efficacy. J Acquir Immune Defic Syndr 2001; 26: 218-24
43. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Medicine 2001; 2: 105-13
44. Veldkamp AI, van Heeswijk RPG, Mulder JW, et al. Steadystate pharmacokinetics of twice daily dosing of saquinavir plus ritonavir in HIV-1 infected individuals. J Acquir Immune Defic Syndr 2001; 27: 344-9
45. Kurowski M, Kaeser B, Sawyer A, et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002; 72: 123-32
46. Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2003; 47: 118-23
47. Marzolini C, Buclin T, Decosterd LA, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23: 394-8
48. Guiard-Schmid JB, Poirier JM, Meynard JL, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 2003; 47: 986-90
49. Vrijens B, Tousset E, Rode R, et al. Within-patient variance reduced in an ARV PI study by switching from patient-reported to electronically monitored dosing times [abstract 846]. 2nd International AIDS Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris
50. Boffito M, Back D, Hoggard PG, et al. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS 2003; 17: 1107-8
51. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73: 20-30
52. Slain D, Pakyz A, Israel DS, et al. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000; 8: 898-907
53. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr 1998; 19: 203-9
54. Masuda S, Uemoto S, Hashiba T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68: 98-103
55. Fellay J, Marzolini C, Meaden ER, et al. Response to antire-troviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmaco-genetics study. Lancet 2002; 359: 30-6
56. Verstuyft C, Marcellin F, Morand-Joubert L, et al. Impact of MDR1 (C3435T) genetic polymorphism in patients naïve treated with HAART including indinavir [abstract 522]. 10th Conference on Retroviruses and Opportunistic Infection; 2003 Feb 10-14; Boston (MA)
57. Aarnouste RE, Brinkman K, Benetucci J, et al. Pharmacokinet-ics of indinavir/ritonavir (800/100mg twice a day) combined with efavirenz in HIV-infected patients. AIDS 2004; 18: 565-7
58. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59: 581-620
59. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30: S171-6